Insider Buying: Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Purchases $116,000.00 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Sumant Ramachandra bought 200,000 shares of the firm’s stock in a transaction that occurred on Friday, March 21st. The shares were purchased at an average cost of $0.58 per share, for a total transaction of $116,000.00. Following the acquisition, the director now directly owns 200,000 shares in the company, valued at $116,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

Lyell Immunopharma Trading Up 6.4 %

Shares of NASDAQ LYEL opened at $0.59 on Friday. The business has a 50-day moving average of $0.61 and a 200-day moving average of $0.87. The firm has a market capitalization of $175.25 million, a price-to-earnings ratio of -0.75 and a beta of -0.41. Lyell Immunopharma, Inc. has a 12 month low of $0.48 and a 12 month high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price target on shares of Lyell Immunopharma in a report on Thursday, March 13th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in LYEL. Centiva Capital LP purchased a new position in shares of Lyell Immunopharma in the 3rd quarter worth about $31,000. Graham Capital Management L.P. bought a new stake in Lyell Immunopharma in the 4th quarter worth approximately $33,000. RPO LLC purchased a new stake in Lyell Immunopharma in the fourth quarter worth approximately $42,000. Intech Investment Management LLC bought a new position in Lyell Immunopharma during the third quarter valued at approximately $52,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Lyell Immunopharma during the third quarter valued at approximately $52,000. Institutional investors own 66.05% of the company’s stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.